Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Third Quarter 2021 Net Revenues Increased 35% to $106.8 Million Year-Over-Year with Adjusted EBITDA Up 27% Year-Over-Year to $24.5 Million First Nine Months Net Revenues Increased 33% to $283.2 Million, with LTM Net Revenues at $401.4 Million and LTM Adjusted EBITDA up to $100.3 Million Strong Double Digit Revenue Growth in Four Out of Five Business Units Driven by Market Share Gains and New Product Launches Closed Business Combination with Union Acquisition Corp. II on September 29, 2021, and Listed on The Nasdaq Global Market Under "PROC" on September 30, 2021 As a Result of the Business Combination, Procaps Group Ended the Third Quarter 2021 with $100.2 Million in Unrestricted Cash a
Combined Company to Begin Trading on the Nasdaq Global Market® Under "PROC" and "PROCW" On September 30, 2021 Approximately $160 Million of Gross Proceeds Strategically Positions Procaps, a Leading Global Pharmaceutical Technology and Healthcare Company Based in Latin America, to Accelerate M&A Roll-Up Initiative and Expand New Product Categories in B2B & B2C Segments Strong First Half 2021 Financial Results Position Procaps to Achieve Prior Full Year 2021 Guidance of Approximately $400 Million in Net Revenues and $105 Million of Adjusted EBITDA Procaps Will be Led by Ruben Minski, Founder, Chairman of the Board and Chief Executive Officer of Procaps Group, and Current Executive Team Inc
Union Acquisition Corp. II ("LATN") Shareholders Approve the Proposed Business Combination with Procaps Group and the Parties Agree to Close by September 30, 2021 Following the Closing of the Business Combination the Combined Company is expected to Trade on the Nasdaq Global Market® Under "PROC" and "PROCW" Union Acquisition Corp. II (NASDAQ:LATN, LATNU, LATNW))) ("LATN"), a publicly-traded special purpose acquisition company, announced today that its shareholders voted to approve the previously announced business combination (the "Business Combination") with Procaps Group, a leading integrated international healthcare and pharmaceutical company, and all other proposals presented at LATN'
15-12B - Union Acquisition Corp. II (0001766146) (Filer)
8-K - Union Acquisition Corp. II (0001766146) (Filer)
8-K - Union Acquisition Corp. II (0001766146) (Filer)
5 - Union Acquisition Corp. II (0001766146) (Issuer)
4 - Union Acquisition Corp. II (0001766146) (Issuer)
4 - Union Acquisition Corp. II (0001766146) (Issuer)
SC 13G/A - Union Acquisition Corp. II (0001766146) (Subject)
SC 13G - Union Acquisition Corp. II (0001766146) (Subject)
SC 13G - Union Acquisition Corp. II (0001766146) (Subject)
Third Quarter 2021 Net Revenues Increased 35% to $106.8 Million Year-Over-Year with Adjusted EBITDA Up 27% Year-Over-Year to $24.5 Million First Nine Months Net Revenues Increased 33% to $283.2 Million, with LTM Net Revenues at $401.4 Million and LTM Adjusted EBITDA up to $100.3 Million Strong Double Digit Revenue Growth in Four Out of Five Business Units Driven by Market Share Gains and New Product Launches Closed Business Combination with Union Acquisition Corp. II on September 29, 2021, and Listed on The Nasdaq Global Market Under "PROC" on September 30, 2021 As a Result of the Business Combination, Procaps Group Ended the Third Quarter 2021 with $100.2 Million in Unrestricted Cash a